Association of DPP-4 activity with BMD, body composition, and incident hip fracture: the Cardiovascular Health Study

Boning up on DPP4, DPP4 substrates, and DPP4-adipokine interactions: Logical reasoning and known facts about bone related effects of DPP4 inhibitors

(2016) Lorenzo Glorie et al.   BONE

Effects of diabetes drugs on the skeleton

(2016) Christian Meier et al.   BONE

DPP-4 inhibitor therapy and bone fractures in people with Type 2 diabetes – A systematic review and meta-analysis

(2016) Jil Mamza et al.   DIABETES RESEARCH AND CLINICAL PRACTICE

Risk of fractures and diabetes medications: a nationwide cohort study

(2016) H. J. Choi et al.   OSTEOPOROSIS INTERNATIONAL

Dipeptidyl peptidase-4 inhibitors as add-on therapy to insulin: rationale and evidences

(2016) Awadhesh Kumar Singh et al.   Expert Review of Clinical Pharmacology

Dipeptidyl peptidase-4 inhibitors and fracture risk: an updated meta-analysis of randomized clinical trials

(2016) Jianying Fu et al.   Scientific Reports

Serum dipeptidyl peptidase-4 is associated with multiple vertebral fractures in type 2 diabetes mellitus

(2015) Masakazu Notsu et al.   CLINICAL ENDOCRINOLOGY

Effect of sitagliptin on intrahepatic lipid content and body fat in patients with type 2 diabetes

(2015) Hiroyuki Kato et al.   DIABETES RESEARCH AND CLINICAL PRACTICE

Plasma DPP4 Activities Are Associated With Osteoporosis in Postmenopausal Women With Normal Glucose Tolerance

(2015) Tianpeng Zheng et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Oral anti-diabetic drugs and fracture risk, cut to the bone: safe or dangerous? A narrative review

(2015) A. Palermo et al.   OSTEOPOROSIS INTERNATIONAL

The fall descriptions and health characteristics of older adults with hip fracture: a mixed methods study

(2015) Breiffni Leavy et al.   BMC Geriatrics

DPP4 in diabetes

(2015) Diana Röhrborn   Frontiers in Immunology

Use of dipeptidyl peptidase-4 inhibitors for type 2 diabetes mellitus and risk of fracture

(2014) Johanna H.M. Driessen et al.   BONE

Management of Hyperglycemia in Type 2 Diabetes, 2015: A Patient-Centered Approach: Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes

(2014) Silvio E. Inzucchi et al.   DIABETES CARE

Shedding of dipeptidyl peptidase 4 is mediated by metalloproteases and up-regulated by hypoxia in human adipocytes and smooth muscle cells

(2014) Diana Röhrborn et al.   FEBS LETTERS

Blockade of CD26 Signaling Inhibits Human Osteoclast Development

(2014) Hiroko Nishida et al.   JOURNAL OF BONE AND MINERAL RESEARCH

UniProt: a hub for protein information

(2014)   NUCLEIC ACIDS RESEARCH

Dipeptidyl Peptidase 4 Is a Novel Adipokine Potentially Linking Obesity to the Metabolic Syndrome

(2011) D. Lamers et al.   DIABETES

Dipeptidyl Peptidase-4 Inhibitors and Bone Fractures: A meta-analysis of randomized clinical trials

(2011) M. Monami et al.   DIABETES CARE

Effects of vildagliptin on postprandial markers of bone resorption and calcium homeostasis in recently diagnosed, well-controlled type 2 diabetes patients*

(2011) Mathijs C. BUNCK et al.   Journal of Diabetes

On the origin of serum CD26 and its altered concentration in cancer patients

(2009) Oscar J. Cordero et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Sitagliptin 100 mg daily effect on DPP-4 inhibition and compound-specific glycemic improvement

(2009) M. Alba et al.   CURRENT MEDICAL RESEARCH AND OPINION

The Murine Glucagon-Like Peptide-1 Receptor Is Essential for Control of Bone Resorption

(2007) Chizumi Yamada et al.   ENDOCRINOLOGY